Please login to the form below

Not currently logged in

UCB reports H1 profit rise

UCB's profit has been boosted by increased sales of core drugs

UCB, the Belgian pharmaceutical company, has posted an 11 per cent increase in pre-tax profit to €443m for the first six months of 2011, reflecting a strong increase in sales.

The company's total revenue for the period increased by 2 per cent to €1.68bn. It reported significant sales growth of new medicines Cimzia (certolizumab pegol - 72 per cent), Vimpat (lacosamide - 76 per cent) and Neupro (rotigotine - 17 per cent). UCB also noted a strong performance of its anti-epileptic drug Keppra (levetiracetam) in Europe and Japan.

Roch Doliveux, CEO, said: "We are excited about the momentum of Cimzia, Vimpat and Neupro, about the potential UCB new medicines from our promising pipeline and about the fact that from 2012 onward, we will have a decade without impacts from major patent expiries."

The company's pipeline has been strengthened with positive phase III results for Cimzia in rheumatoid arthritis and Neupro for advanced Parkinson's disease.

29th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...